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Introduction
• Long ago, in Block 6…
Introduction
• Diagnosis: Erythrodermic Psoriasis (secondary to oral 
corticosteroids for plaque psoriasis)
Introduction
• For decades, dermatology teachings have cautioned against 
the use of orally administered glucocorticoids (OAG) in the 
treatment of psoriasis
• This is due to classically feared outcomes of generalized 
pustular psoriasis (GPP) and erythrodermic psoriasis (EP)
• However, evidence shows that oral glucocorticoids are used 
at high rates in the U.S. and Europe, often by dermatologists
Introduction
• Despite widespread use, there is scant data on treatment 
outcomes
• Only one recent study (Gregoire 2020) has examined this 
and found that rates of severe psoriasis flares may be low,
• The authors reported 1 case of erythroderma and no 
pustular psoriasis among 1,970 patients treated with steroids 
for psoriasis
Introduction
• We see an urgency to examine the relationship between 
oral glucocorticoid usage and the development of GPP and 
EP
• Demonstration of the safety of oral glucocorticoid use in 




– What is the prevalence of orally administered 
glucocorticoid use in the management of plaque 
psoriasis by U.S. dermatologists and the incidence of GPP 
and EP in this context?
• Hypothesis
– The use of orally administered glucocorticoids is not 
infrequent among US dermatologists and rarely 
complicated by GPP or EP
Approach & Results
• Study design 
– Online survey
• Population / study sample
– 143 US community and university-based dermatologists
• Outcome (dependent variable(s))
– Prevalence of oral glucocorticoids in the management of Plaque 
Psoriasis
– Incidence of of GPP and EP in the context of oral glucocorticoid 
tapering
• Data source and collection 
– Written, self-administered, anonymous, closed format questionnaire
• Rationale for Approach
– To our knowledge, there are no prospective studies on OAG usage-
related studies involving psoriasis and GPP/EP






– 50 out of 143 U.S. community and university-based dermatologists 
completed the survey
– Most dermatologists surveyed have been in clinical practice greater 
than 10 years and see 6-10 patients with psoriasis per week
Approach & Results
• Findings
– 9 out of 50 (18%) of respondents reported occasionally prescribing 
OAG to patients with psoriasis, typically 1-5% of the time
– Dermatologists who prescribe OAG tended to be younger than 









– 8 out of 50 (16%) of respondents had experienced one or more 
patients developing GPP/EP in the presence of OAG treatment
– All respondents (98%) were aware of the risk in patients with 
psoriasis of developing GPP and EP in the context of OAG treatment
– GPP was most commonly seen, while EP was not noted





ENCOUNTERED GPP/EP DURING ORAL 
GLUCOCORTICOID USE FOR PSORIASIS
Conclusions
• OAG for the management of psoriasis is not uncommon 
among U.S. dermatologists, despite nearly universal 
awareness of its risks
• A substantial percentage of respondents have seen at least 1 
case of OAG-related GPP/EP
• However, in view of the high prevalence of psoriasis in the 
U.S., the actual rate may be low
• If OAG is to be accepted as as a safe psoriasis therapeutic, 
prospective studies are needed to fully characterize their 
risk/benefit profile
Future Directions
• We are submitting a brief report to JAMA Derm
• We plan to conduct a similar study in a European 
population
• This is the first step towards further prospective studies on 
OAG use in psoriasis and outcomes of GPP and EP
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